<?xml version="1.0" encoding="UTF-8"?>
<ref id="B148-pharmaceutics-12-00171">
 <label>148.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Savage</surname>
    <given-names>A.C.</given-names>
   </name>
   <name>
    <surname>Tatham</surname>
    <given-names>L.M.</given-names>
   </name>
   <name>
    <surname>Siccardi</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Scott</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Vourvahis</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Clark</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Rannard</surname>
    <given-names>S.P.</given-names>
   </name>
   <name>
    <surname>Owen</surname>
    <given-names>A.</given-names>
   </name>
  </person-group>
  <article-title>Improving maraviroc oral bioavailability by formation of solid drug nanoparticles</article-title>
  <source>Eur. J. Pharm. Biopharm.</source>
  <year>2019</year>
  <volume>138</volume>
  <fpage>30</fpage>
  <lpage>36</lpage>
  <pub-id pub-id-type="doi">10.1016/j.ejpb.2018.05.015</pub-id>
  <pub-id pub-id-type="pmid">29777772</pub-id>
 </element-citation>
</ref>
